Reynolds CP - Search Results

1

Assessing combinations of cytotoxic agents using leukemia cell lines.

Reynolds CP, Kang MH, Keshelava N, Maurer BJ. Reynolds CP, et al. Curr Drug Targets. 2007 Jun;8(6):765-71. doi: 10.2174/138945007780830845. Curr Drug Targets. 2007. PMID: 17584032

2

Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53.

Keshelava N, Tsao-Wei D, Reynolds CP. Keshelava N, et al. Among authors: reynolds cp. Clin Cancer Res. 2003 Aug 15;9(9):3492-502. Clin Cancer Res. 2003. PMID: 12960142

3

DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.

Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP. Keshelava N, et al. Among authors: reynolds cp. Methods Mol Med. 2005;110:139-53. doi: 10.1385/1-59259-869-2:139. Methods Mol Med. 2005. PMID: 15901933 Review.

4

Evaluating response to antineoplastic drug combinations in tissue culture models.

Reynolds CP, Maurer BJ. Reynolds CP, et al. Methods Mol Med. 2005;110:173-83. doi: 10.1385/1-59259-869-2:173. Methods Mol Med. 2005. PMID: 15901935 Review.

5

Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.

Yang B, Keshelava N, Anderson CP, Reynolds CP. Yang B, et al. Among authors: reynolds cp. Cancer Res. 2003 Apr 1;63(7):1520-6. Cancer Res. 2003. PMID: 12670899

6

Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.

Keshelava N, Seeger RC, Groshen S, Reynolds CP. Keshelava N, et al. Among authors: reynolds cp. Cancer Res. 1998 Dec 1;58(23):5396-405. Cancer Res. 1998. PMID: 9850071

7

Retinoid therapy of high-risk neuroblastoma.

Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Reynolds CP, et al. Cancer Lett. 2003 Jul 18;197(1-2):185-92. doi: 10.1016/s0304-3835(03)00108-3. Cancer Lett. 2003. PMID: 12880980 Review.

8

Ceramide synthesis and metabolism as a target for cancer therapy.

Reynolds CP, Maurer BJ, Kolesnick RN. Reynolds CP, et al. Cancer Lett. 2004 Apr 8;206(2):169-80. doi: 10.1016/j.canlet.2003.08.034. Cancer Lett. 2004. PMID: 15013522 Review.

9

Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.

Batra S, Reynolds CP, Maurer BJ. Batra S, et al. Among authors: reynolds cp. Cancer Res. 2004 Aug 1;64(15):5415-24. doi: 10.1158/0008-5472.CAN-04-0377. Cancer Res. 2004. PMID: 15289350

10

In vitro testing of chemosensitivity in physiological hypoxia.

Grigoryan R, Keshelava N, Anderson C, Reynolds CP. Grigoryan R, et al. Among authors: reynolds cp. Methods Mol Med. 2005;110:87-100. doi: 10.1385/1-59259-869-2:087. Methods Mol Med. 2005. PMID: 15901930

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters